Patients’ and CLL characteristics
| Patients’ and CLL characteristics . | Patients (n = 60) . |
|---|---|
| Median age, y (range) | 81 (80-87) |
| Male, n (%) | 33 (55) |
| Female, n (%) | 27 (45) |
| Total CIRS score > 6, n (%) | 46 (76.6) |
| Preexistent cardiovascular risk factors, n (%) | |
| Hypertension | 38 (63.3) |
| Diabetes | 8 (13.3) |
| Dyslipidemia | 6 (10) |
| Obesity | 6 (10) |
| Arteriopathy | 3 (5) |
| No known CV risk factors | 14 (23.3) |
| ≥2 CV risk factors | 14 (23.3) |
| Concomitant cardioactive therapies, n (%) | |
| At least 1 cardioactive drug | 44 (73.3) |
| >2 cardioactive drugs | 18 (10.8) |
| Antihypertensive drugs | 38 (63.3) |
| Anticoagulants | 3 (5) |
| Lipid-lowering drugs | 10 (16.7) |
| Antiplatelets drugs | 21 (35) |
| Prior cardiovascular events, n (%) | |
| Atrial fibrillation | 3 (5) |
| NSTEMI | 3 (5) |
| STEMI | 2 (3.3) |
| Cerebrovascular events | 5 (8.3) |
| Echocardiographic baseline evaluation | |
| Left ventricular ejection fraction, % | 41 (±6.7) |
| Left atrial diameter, mm | 47 (±11.6) |
| IGHV mutational status, n (%) | |
| Mutated | 24 (40) |
| Unmutated | 32 (53.3) |
| Not determined | 2 (3.3) |
| Not performed | 2 (3.3) |
| Cytogenetic subgroup, n (%) | |
| Deletion in 17p | 20 (33.3) |
| Deletion in 11q | 12 (20) |
| Deletion in 13q alone | 6 (10) |
| Trisomy 12 | 5 (8.3) |
| No abnormalities | 10 (16.7) |
| Not performed | 7 (11.6) |
| TP53 mutational status, n (%) | |
| Mutated | 19 (31.7) |
| Unmutated | 34 (56.7) |
| Not performed | 7 (11.6) |
| Anti-infective prophylaxis and vaccinations | |
| Trimethoprim-sulfamethoxazole | 35 (58) |
| Acyclovir | 39 (65) |
| Vaccination for SARS-CoV-2 | 40 (66.7) |
| Seasonal influenza vaccine | 38 (63.3) |
| Pneumococcal vaccine | 17 (28.3) |
| Baseline immunoglobulin mean values | |
| IgA | 1.93 g/L |
| IgM | 1.09 g/L |
| IgG | 11.7 g/L |
| Precedent therapies | |
| Treatment naïve patients | 20 (33.3) |
| Relapsed/refractory patients | 40 (66.6) |
| Medium number of previous lines | 1 (range, 0-8) |
| Chlorambucil+rituximab | 22 (36.6) |
| Bendamustine+rituximab | 20 (33.3) |
| Fludarabine-cyclophosphamide+rituximab | 6 (10) |
| Ofatumumab | 2 (3.3) |
| Alemtuzumab | 1 (1.6) |
| Patients’ and CLL characteristics . | Patients (n = 60) . |
|---|---|
| Median age, y (range) | 81 (80-87) |
| Male, n (%) | 33 (55) |
| Female, n (%) | 27 (45) |
| Total CIRS score > 6, n (%) | 46 (76.6) |
| Preexistent cardiovascular risk factors, n (%) | |
| Hypertension | 38 (63.3) |
| Diabetes | 8 (13.3) |
| Dyslipidemia | 6 (10) |
| Obesity | 6 (10) |
| Arteriopathy | 3 (5) |
| No known CV risk factors | 14 (23.3) |
| ≥2 CV risk factors | 14 (23.3) |
| Concomitant cardioactive therapies, n (%) | |
| At least 1 cardioactive drug | 44 (73.3) |
| >2 cardioactive drugs | 18 (10.8) |
| Antihypertensive drugs | 38 (63.3) |
| Anticoagulants | 3 (5) |
| Lipid-lowering drugs | 10 (16.7) |
| Antiplatelets drugs | 21 (35) |
| Prior cardiovascular events, n (%) | |
| Atrial fibrillation | 3 (5) |
| NSTEMI | 3 (5) |
| STEMI | 2 (3.3) |
| Cerebrovascular events | 5 (8.3) |
| Echocardiographic baseline evaluation | |
| Left ventricular ejection fraction, % | 41 (±6.7) |
| Left atrial diameter, mm | 47 (±11.6) |
| IGHV mutational status, n (%) | |
| Mutated | 24 (40) |
| Unmutated | 32 (53.3) |
| Not determined | 2 (3.3) |
| Not performed | 2 (3.3) |
| Cytogenetic subgroup, n (%) | |
| Deletion in 17p | 20 (33.3) |
| Deletion in 11q | 12 (20) |
| Deletion in 13q alone | 6 (10) |
| Trisomy 12 | 5 (8.3) |
| No abnormalities | 10 (16.7) |
| Not performed | 7 (11.6) |
| TP53 mutational status, n (%) | |
| Mutated | 19 (31.7) |
| Unmutated | 34 (56.7) |
| Not performed | 7 (11.6) |
| Anti-infective prophylaxis and vaccinations | |
| Trimethoprim-sulfamethoxazole | 35 (58) |
| Acyclovir | 39 (65) |
| Vaccination for SARS-CoV-2 | 40 (66.7) |
| Seasonal influenza vaccine | 38 (63.3) |
| Pneumococcal vaccine | 17 (28.3) |
| Baseline immunoglobulin mean values | |
| IgA | 1.93 g/L |
| IgM | 1.09 g/L |
| IgG | 11.7 g/L |
| Precedent therapies | |
| Treatment naïve patients | 20 (33.3) |
| Relapsed/refractory patients | 40 (66.6) |
| Medium number of previous lines | 1 (range, 0-8) |
| Chlorambucil+rituximab | 22 (36.6) |
| Bendamustine+rituximab | 20 (33.3) |
| Fludarabine-cyclophosphamide+rituximab | 6 (10) |
| Ofatumumab | 2 (3.3) |
| Alemtuzumab | 1 (1.6) |
IGHV, immunoglobulin heavy chain.